K01TW013200

IMPACT OF MULTIDISCIPLINARY EVALUATION OF TREATMENT AND OUTCOME FOR HEPATOCELLULAR CARCINOMA IN TANZANIA - PROJECT SUMMARY THIS MENTORED IRSDA-K01 FROM UNIVERSITY OF CALIFORNIA DAVIS (UCD) AND MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED HEALTH SCIENCE (MUHAS) TANZANIA WILL SUPPORT DR. CAMERON GASKILL, ASSISTANT PROFESSOR OF SURGERY, TO ESTABLISH AN IMPACTFUL, INDEPENDENT GLOBAL HEALTH RESEARCH PROGRAM ADDRESSING LIVER CANCER IN SUB-SAHARAN AFRICA (SSA). LIVER CANCER, OR HEPATOCELLULAR CARCINOMA (HCC), IS THE THIRD LEADING CAUSE OF CANCER RELATED MORTALITY WORLDWIDE. IN SSA, < 5% OF PATIENTS RECEIVE CURATIVE TREATMENTS. IN TANZANIA, IMPROVING CARE FOR HCC PATIENTS HAS BECOME A TOP PRIORITY FOR THE MINISTRY OF HEALTH. THIS K01 WILL ESTABLISH A KNOWLEDGE BASE AND INFRASTRUCTURE THAT PROSPECTIVELY CAPTURES HIGHLY ANNOTATED TREATMENT INFORMATION AND OUTCOME METRICS. THE GOAL IS TO EVALUATE CARE DELIVERY FACTORS AND IDENTIFY AREAS TO EXPAND CURATIVE TREATMENT STRATEGIES CULMINATING IN A CLINICAL TRIAL INVESTIGATING THE SAFETY AND EFFICACY OF SURGICAL RESECTION FOR HCC BEYOND CURRENT PRACTICES. THE AIMS ARE TO 1) PILOT A NATIONAL LIVER CANCER TREATMENT OUTCOMES REGISTRY TO ASSESS THE IMPACT OF LOCATION AND RESOURCE AVAILABILITY; 2) UTILIZE MULTIDISCIPLINARY TUMOR BOARD PERFORMANCE INDEX TO ASSESS IMPACTS OF THE MULTIDISCIPLINARY LIVER TUMOR BOARD ON CARE DELIVERY AND OUTCOMES IN TANZANIA; AND 3) EVALUATE THE SAFETY AND EFFICACY OF CURATIVE SURGICAL RESECTION OF HCC EXTENDED BEYOND BARCELONA CLINIC LIVER CANCER STAGING RECOMMENDATIONS. PAIRED WITH THESE RESEARCH AIMS, THE TRAINING GOALS WILL PROVIDE DR. GASKILL WITH THE SKILLS AND EXPERIENCES NECESSARY TO BUILD AN INDEPENDENT GLOBAL HEALTH RESEARCH PROGRAM AS WELL AS RUN CLINICAL TRIALS IN SSA. THE TRAINING GOALS WILL DEVELOP SKILLS TO 1) IMPLEMENT CLINICAL REGISTRIES; 2) ASSESS KEY PERFORMANCE INDICATORS OF CLINICAL PROGRAMS; 3) PERFORM ADVANCED STATISTICAL ANALYSIS OF EPIDEMIOLOGIC AND CLINICAL DATA; 4) DESIGN EFFECTIVE AND RESOURCE APPROPRIATE CLINICAL TRIALS; 5) BECOME AN EFFECTIVE GLOBAL ONCOLOGY LEADER AND MENTOR; 6) DEVELOP AN R- LEVEL PROPOSAL BASED ON THESE RESEARCH FINDINGS. THROUGH THIS PROCESS DR. GASKILL WILL CULTIVATE THE LEADERSHIP, PROFESSIONAL SKILLS, AND RESEARCH PARTNERSHIPS NECESSARY TO BECOME AN INDEPENDENT GLOBAL HEALTH RESEARCH SCIENTIST. DR. GASKILL WILL BE GUIDED BY A TEAM OF EXPERIENCED MENTORS LED BY DR. ELIA MMBAGA (LMIC MENTOR, MUHAS), A GLOBALLY RECOGNIZED LEADER IN CANCER EPIDEMIOLOGY IN TANZANIA, AND DR. BRAD POLLOCK (UCD MENTOR), NATIONAL LEADER WITH EXPERTISE IN EPIDEMIOLOGY AND CLINICAL TRIAL STUDY DESIGN. IN ADDITION, AN OUTSTANDING TEAM OF CONTRIBUTORS WILL PROVIDE CONTENT EXPERTISE INCLUDING DR. KATHERINE VAN LOON, GLOBAL CANCER CARE RESEARCH, TRAINING, AND LEADERSHIP EXPERTISE, DR. ALLY MWANGA, HEPATOBILIARY SURGERY AND GLOBAL ONCOLOGY RESEARCH EXPERTISE AT MUHAS, AND DR. EDWARD KIM, CLINICAL TRIAL DESIGN AND ADMINISTRATION EXPERTISE AT UCD. THE PROLONGED FIELD EXPERIENCE AND COLLABORATIVE RESEARCH SUPPORTED BY THIS IRSDA-K01, COUPLED WITH STRONG INSTITUTIONAL SUPPORT FROM UCD WILL CULTIVATE A SUSTAINED INTERNATIONAL RESEARCH PARTNERSHIP WITH DR. GASKILL AND MUHAS AIMED AT IMPROVING HCC OUTCOMES IN SSA.

Davis University Of California

THE JOHN E. FOGARTY INTERNATIONAL CENTER (FIC) SUPPORTS RESEARCH AND RESEARCH TRAINING TO REDUCE DISPARITIES IN GLOBAL HEALTH AND TO FOSTER PARTNERSHIPS BETWEEN U.S. SCIENTISTS AND THEIR COUNTERPARTS ABROAD. FIC SUPPORTS BASIC BIOLOGICAL, BEHAVIORAL, AND SOCIAL SCIENCE RESEARCH, AS WELL AS RELATED RESEARCH TRAINING AND CAREER DEVELOPMENT. THE RESEARCH PORTFOLIO IS DIVIDED INTO SEVERAL PROGRAMS THAT SUPPORT A WIDE VARIETY OF FUNDING MECHANISMS TO MEET PROGRAMMATIC OBJECTIVES.

93.989 - International Research and Research Training

Fogarty International Center (FIC) [HHS - NIH]

Davis, California 95616 United States

Single Zip Code

International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) (PAR-24-114)